NO20080420L - Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet - Google Patents

Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet

Info

Publication number
NO20080420L
NO20080420L NO20080420A NO20080420A NO20080420L NO 20080420 L NO20080420 L NO 20080420L NO 20080420 A NO20080420 A NO 20080420A NO 20080420 A NO20080420 A NO 20080420A NO 20080420 L NO20080420 L NO 20080420L
Authority
NO
Norway
Prior art keywords
prolonged release
dependent solubility
active ingredients
release formulation
active ingredient
Prior art date
Application number
NO20080420A
Other languages
English (en)
Norwegian (no)
Inventor
Gareth Lewis
Frederic Andre
Gerard Alaux
Veronique Serre
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080420(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20080420L publication Critical patent/NO20080420L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20080420A 2005-06-28 2008-01-22 Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet NO20080420L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0506539A FR2887455B1 (fr) 2005-06-28 2005-06-28 Formulation a liberation prolongee de principes actifs de medicaments
PCT/FR2006/001466 WO2007003746A1 (fr) 2005-06-28 2006-06-26 Formulation a liberation prolongee de principes actifs presentant une solubilite dependante du ph

Publications (1)

Publication Number Publication Date
NO20080420L true NO20080420L (no) 2008-01-22

Family

ID=35708770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080420A NO20080420L (no) 2005-06-28 2008-01-22 Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet

Country Status (31)

Country Link
US (1) US20080089936A1 (fr)
EP (1) EP1904037A1 (fr)
JP (1) JP2008546830A (fr)
KR (1) KR101387839B1 (fr)
CN (1) CN101217943B (fr)
AR (1) AR057410A1 (fr)
AU (1) AU2006264856B2 (fr)
BR (1) BRPI0612990A2 (fr)
CA (1) CA2611125A1 (fr)
CR (1) CR9567A (fr)
DO (1) DOP2006000144A (fr)
EA (1) EA013745B1 (fr)
EC (1) ECSP078010A (fr)
FR (1) FR2887455B1 (fr)
GT (1) GT200600275A (fr)
HK (1) HK1122731A1 (fr)
HN (1) HN2006023741A (fr)
IL (1) IL187901A0 (fr)
MA (1) MA29560B1 (fr)
MX (1) MX2007016238A (fr)
MY (1) MY150069A (fr)
NO (1) NO20080420L (fr)
NZ (1) NZ564069A (fr)
PA (1) PA8682701A1 (fr)
PE (1) PE20070098A1 (fr)
TN (1) TNSN07438A1 (fr)
TW (1) TWI446934B (fr)
UA (1) UA91553C2 (fr)
UY (1) UY29637A1 (fr)
WO (1) WO2007003746A1 (fr)
ZA (1) ZA200711035B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090297A1 (fr) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formules de flibanserine
WO2013040442A1 (fr) * 2011-09-14 2013-03-21 Pozen Inc. Administration progressive de clopidogrel
IT201700011337A1 (it) * 2017-02-02 2018-08-02 S I I T S R L Servizio Int Imballaggi Termosaldanti Compressa multistrato per la somministrazione di magnesio

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
AU679906B2 (en) * 1992-01-17 1997-07-17 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
EP1005863A1 (fr) * 1998-12-04 2000-06-07 Synthelabo Formes galeniques a liberation controlee contenant un hypnotique a activite courte ou un sel de ce compose
WO2000040205A2 (fr) * 1999-01-05 2000-07-13 Copley Pharmaceutical Inc. Formulation a liberation continue ayant une sensibilite limitee a l'humidite
EP1064937A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à liberation controllée comprenant un hypnotique à courte duree ou une des ses sels
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
WO2005044199A2 (fr) * 2003-11-05 2005-05-19 Santarus, Inc. Combinaison d'un inhibiteur de pompe a protons et d'un agent favorisant le sommeil

Also Published As

Publication number Publication date
GT200600275A (es) 2007-03-29
AU2006264856A1 (en) 2007-01-11
WO2007003746A1 (fr) 2007-01-11
PE20070098A1 (es) 2007-03-01
JP2008546830A (ja) 2008-12-25
HK1122731A1 (en) 2009-05-29
DOP2006000144A (es) 2007-02-28
KR101387839B1 (ko) 2014-04-22
MA29560B1 (fr) 2008-06-02
MY150069A (en) 2013-11-29
US20080089936A1 (en) 2008-04-17
TNSN07438A1 (en) 2009-03-17
HN2006023741A (es) 2011-05-31
EA013745B1 (ru) 2010-06-30
MX2007016238A (es) 2008-03-06
CN101217943B (zh) 2012-05-23
FR2887455A1 (fr) 2006-12-29
BRPI0612990A2 (pt) 2011-04-19
CA2611125A1 (fr) 2007-01-11
UY29637A1 (es) 2007-01-31
AU2006264856B2 (en) 2011-09-15
FR2887455B1 (fr) 2007-08-10
ECSP078010A (es) 2008-01-23
UA91553C2 (ru) 2010-08-10
AR057410A1 (es) 2007-12-05
TWI446934B (zh) 2014-08-01
IL187901A0 (en) 2008-03-20
ZA200711035B (en) 2009-09-30
TW200727921A (en) 2007-08-01
KR20080019023A (ko) 2008-02-29
CR9567A (es) 2008-02-20
EP1904037A1 (fr) 2008-04-02
EA200800150A1 (ru) 2008-04-28
NZ564069A (en) 2012-04-27
CN101217943A (zh) 2008-07-09
PA8682701A1 (es) 2007-01-17

Similar Documents

Publication Publication Date Title
NO20034323L (no) Medisinske aerosolformuleringer
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
ATE373422T1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
WO2007037795A3 (fr) Formulations pharmaceutiques
RS50360B (sr) Farmaceutske formulacije derivata platine
AR097045A2 (es) Sistema terapéutico transdérmico
CY1109272T1 (el) Συνθεση παρατεταμενης απελευθερωσεως περιλαμβανουσα συμπολυμερες γαλακτικου οξεος-γλυκολικου οξεος και μεθοδος παρασκευης της
CY1114769T1 (el) Διασπαρσιμα στο νερο αγροχημικα σκευασματα που αποτελουνται απο πολυαλκοξυτριγλυκεριδια ως υποκινητες διεισδυσης
NO20071667L (no) Farmasoytisk preparat omfattende levetiracetam og fremgangsmate for fremstilling av preparatet
EA200870379A1 (ru) Фармацевтическая композиция с замедленным высвобождением на основе системы высвобождения, включающей кислоторастворимый полимер и ph-зависимый полимер
CY1111458T1 (el) Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
CY1108766T1 (el) Συνθεσεις και μεθοδοι για την προληψη ή την μειωση της αντοχης των εντομων στα εντομοκτονα
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
NO20080420L (no) Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet
CY1114586T1 (el) Συνθεση φορεα για τη μεταφορα νουκλεϊνικων οξεων
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
BRPI0513244A (pt) composto de clatrato, método para controlar a concentração de solução aquosa de ingrediente ativo quìmico agrìcola e formulação quìmica agrìcola
FR2882522B1 (fr) Composition pharmaceutique solide comprenant de la telithromycine
AR040287A1 (es) Plataforma para formulaciones transdermicas (pft)
BR0311479A (pt) Derivados de tiofeno antelmìnticos e inseticidas
ITRM20040168A1 (it) Composizione a rilascio modificato ph dipendente.
Fitzsimmons et al. Nitric oxide inhibition of Rickettsia rickettsii
BRPI0407456A (pt) Derivados antiproliferativos de 2-(sulfo-fenil)-aminotiazole e composições farmacêuticas, e métodos para o seu uso
DK1254944T3 (da) Törre sammensætninger, der indeholder hydrofob aminosyre

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application